Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen
Phase of Trial: Phase III
Latest Information Update: 28 Jul 2017
Price : $35 *
At a glance
- Drugs Raltegravir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate
- Indications HIV-1 infections
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 18 Jul 2017 Status changed from active, no longer recruiting to completed.
- 20 Apr 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Jun 2016.